S83463 |
Adomeglivant |
源葉(MedMol) | ≥98% |
- 提示:詳情請(qǐng)下載說明書。
- 產(chǎn)品描述: Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus
- 靶點(diǎn): GluR;GlucagonReceptor
- 體外研究:
Adomeglivant dose-dependently blocks glucagon-induced the raise levels of cAMP in HEK293-GluR cells. Adomeglivant fails to block cAMP-elevating actions of adenosine. Adomeglivant exhibits high selectivity for family B GPCRs, and specifically interacts with a conserved binding motif within the GluR, GLP-1R, and GIP-R
- 體內(nèi)研究:
Adomeglivant (5 mg/kg; i.p.) completely abolishes the hyperglycaemic action of CNO (clozapine-N-oxide) in Avpires-Cre+ mice. (CNO is a specific, pharmacologically inert agonist for hM3Dq-induced membrane depolarisation and increased the firing rate in hM3Dq-expressing arginine-vasopressin (AVP) neurons.) Animal Model: Avpires-Cre+ mice Dosage: 5 mg/kg Administration: Intraperitoneal injection, 30 minutes prior to CNO Result: Completely abolished the hyperglycaemic action of CNO.
- 參考文獻(xiàn):
1. Sonam Grover, et al. Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus. BMC Bioinformatics. 2014; 15(Suppl 16): S13. 2. Oleg G Chepurny, et al. Non-conventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. J Biol Chem. 2019 Mar 8;294(10):3514-3531. 3. Angela Kim, et al. AVP-induced counter-regulatory glucagon is diminished in type 1 diabetes. bioRxiv. January 31, 2020.
- 溶解性: soluble in DMSO
- 保存條件: -20°C
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 1.8 ml 8.999 ml 17.998 ml 5 mM 0.36 ml 1.8 ml 3.6 ml 10 mM 0.18 ml 0.9 ml 1.8 ml 50 mM 0.036 ml 0.18 ml 0.36 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):
本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)